Effect of whole-body vibration and insulin-like growth factor-I on muscle paralysis-induced bone degeneration after botulinum toxin injection in mice

Alpha-solanine inhibits cell proliferation via mitochondrial dysfunction and inhibin synthesis in mouse testis In vitro and In vivo

Sertoli and Leydig cells provide key supporting roles in spermatogenesis. Various toxins have been studied in the TM3 and TM4 mouse testis cell lines to identify their regulatory effects. Alpha-solanine (α-solanine), a toxic compound found in the potato, has cytotoxic effects on various cells, including cancer cells. However, the effect of α-solanine on testis function has not been identified. In this study, we verified for the first time the anti-proliferative effect of α-solanine in mouse testes. α-Solanine reduced cell viability in TM3 and TM4 cells and reduced the expression of the cell cycle checkpoint genes Ccnd1 and Ccne1. We also detected changes in the mitochondrial membrane potential (MMP) and in the cytosolic calcium and intracellular signal pathways in both cell lines. α-Solanine induced AKT, P70S6K, S6, ERK1/2, and JNK activation in mouse testis cells. In addition, the inhibition of AKT with a pharmacological inhibitor (LY294002) demonstrated more synergic anti-proliferative effects than in the TM3 and TM4 cell lines treated only with α-solanine. Inha and Inhba mRNA expression also decreased in both cell lines and α-solanine i.p. injected mouse testes. Collectively, the results from this study verify the toxic effects of α-solanine on testes and male reproductive function.

Muscle-bone interactions: From experimental models to the clinic? A critical update

Bone is a biomechanical tissue shaped by forces from muscles and gravitation. Simultaneous bone and muscle decay and dysfunction (osteosarcopenia or sarco-osteoporosis) is seen in ageing, numerous clinical situations including after stroke or paralysis, in neuromuscular dystrophies, glucocorticoid excess, or in association with vitamin D, growth hormone/insulin like growth factor or sex steroid deficiency, as well as in spaceflight. Physical exercise may be beneficial in these situations, but further work is still needed to translate acceptable and effective biomechanical interventions like vibration therapy from animal models to humans. Novel antiresorptive and anabolic therapies are emerging for osteoporosis as well as drugs for sarcopenia, cancer cachexia or muscle wasting disorders, including antibodies against myostatin or activin receptor type IIA and IIB (e.g. bimagrumab). Ideally, increasing muscle mass would increase muscle strength and restore bone loss from disuse. However, the classical view that muscle is unidirectionally dominant over bone via mechanical loading is overly simplistic. Indeed, recent studies indicate a role for neuronal regulation of not only muscle but also bone metabolism, bone signaling pathways like receptor activator of nuclear factor kappa-B ligand (RANKL) implicated in muscle biology, myokines affecting bone and possible bone-to-muscle communication. Moreover, pharmacological strategies inducing isolated myocyte hypertrophy may not translate into increased muscle power because tendons, connective tissue, neurons and energy metabolism need to adapt as well. We aim here to critically review key musculoskeletal molecular pathways involved in mechanoregulation and their effect on the bone-muscle unit as a whole, as well as preclinical and emerging clinical evidence regarding the effects of sarcopenia therapies on osteoporosis and vice versa.